

Erratum

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease

Diane Stephenson, Derek Hill, Jesse M. Cedarbaum, Maria Tome, Spiros Vamvakas, Klaus Romero, Daniela J. Conrado, David T. Dexter, John Seibyl, Danna Jennings, Timothy Nicholas, Dawn Matthews, Zhiyong Xie, Syed Imam, Paul Maguire, David Russell, Mark Forrest Gordon, Glenn T. Stebbins, Ed Somer, Jill Gallagher, Arthur Roach, Peter Basseches, Donald Grosset and Ken Marek on behalf of the Critical Path for Parkinson's Consortium

[Journal of Parkinson's Disease, 9(3) (2019), 553–563, DOI 10.3233/JPD-191648]
<https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd191648>

On page 560, the following Disclaimer was missing from the published article:

The findings and conclusions in this publications by the authors from US Food and Drug Administration are those of the authors and do not necessarily represent the views of the FDA.